PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,777.00
Bid: 1,776.50
Ask: 1,777.50
Change: -6.50 (-0.36%)
Spread: 1.00 (0.056%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain's FTSE dips on Ukraine nerves; RBS outperforms

Fri, 25th Jul 2014 16:15

* FTSE 100 closes down 0.4 pct after late selloff

* Traders run for exit as Russia accuses Ukraine of selling

* RBS jumps 11 pct as UK upturn boosts results

* BSkyB falls 5.5 pct on news of 4.9 bln pound acquisition

By Francesco Canepa

LONDON, July 25 (Reuters) - Britain's main equity indexclosed lower on Friday as new tensions between Russia andUkraine and falls on Wall Street led traders to cash in on theirweekly gains just before the close.

The FTSE 100 closed 29.91 points, or 0.4 percentlower, at 6,791.55 points, erasing nearly half its weekly gainsin the last hour of trading after Russia accused Ukraine ofhaving shelled across the border.

U.S. indexes also fell, partly weighed down by weak resultsfrom online retailer Amazon and a revenue warning fromthe world's largest credit and debit card company, Visa.

Investors were reluctant to hold on to their long positionsinto the weekend as the geopolitical landscape remainsuncertain.

"There's uncertainty out there in Ukraine and the market hada bit of an exit move," Mark Priest, a senior trader at ETXCapital, said.

BSkyB was the heaviest faller on the FTSE, sliding5.5 percent, after the company placed shares representing nearly10 percent of its capital to finance part of its acquisition ofSky Deutschland and Sky Italia.

Shares in RBS, however, surged 10.8 percent, their biggestrise in four years, after the bank posted a surprise pretaxprofit for the second quarter, citing an economic upturn thatallowed it to write back losses that had been booked on badloans.

Fellow British-focused lenders Barclays and LloydsBanking Group, which are due to report next week, wereup more than 1 percent.

"Credit quality keeps improving, especially in distressedassets such as commercial real estate," said Espirito Santoanalyst Shailesh Raikundlia, who has a "neutral" recommendationon the stock.

"In general, the credit environment is pretty benign andthat should come through in banks' results."

The positive mood on the British economy was underpinned bydata showing economic output in the second quarter finallytopped levels seen before the financial crisis struck six yearsago.

Network operator Vodafone added 4.4 points to theFTSE as it rose 2.1 percent after saying its performance hadbegun to stabilise in several European markets.

Pegging back the index were export-oriented companies suchas heavyweight drugs firm GlaxoSmithKline and fashionbrand Burberry.

GSK knocked 8.9 points off the index as it faced newallegations of corruption, this time in Syria, where thedrugmaker and its distributor have been accused of paying bribesto secure business, according to a whistleblower's email.

Burberry fell 1.6 percent after French luxury goods groupLVMH posted below-forecast second-quarter sales andprofits, hit by a drop in demand from China. (Additional reporting by Lionel Laurent; Editing by SusanFenton)

More News
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.